Associated Papers
Current paradigm of EGFRins20 in non-small cell lung cancer: A long way forward.
Miyamura BV et al.
Med (new York, N.y.), 2025
Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A Systematic Literature Review.
Vadagam P et al.
Current Oncology (toronto, Ont.), 2025
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer.
Park S et al.
European Journal of Cancer (oxford, England : 1990), 2024
Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
Hirotsu Y et al.
Scientific Reports, 2024
EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies.
Bai Q et al.
Cancer Treatment Reviews, 2023
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.
Elamin YY et al.
Cancer Cell, 2022
Analysis of single-nucleotide polymorphisms in genes associated with triple-negative breast cancer.
G V et al.
Frontiers in Genetics, 2022
Pancreatic Cancer-Related Mutational Burden Is Not Increased in a Patient Cohort With Clinically Severe Chronic Pancreatitis.
Cowan RW et al.
Clinical and Translational Gastroenterology, 2021
Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates.
Meador CB et al.
Cancer Discovery, 2021
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer.
Pacini L et al.
Pharmacogenomics and Personalized Medicine, 2021
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins.
Remon J et al.
Cancer Treatment Reviews, 2020
Uncommon EGFR Mutations in Non-Small Cell Lung Cancer and Their Impact on the Treatment.
Bílek O et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti, 2019
Uncommon EGFR mutations in advanced non-small cell lung cancer.
O'Kane GM et al.
Lung Cancer (amsterdam, Netherlands), 2017
Drug-sensitive FGFR3 mutations in lung adenocarcinoma.
Chandrani P et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2017
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.
Stewart EL et al.
Translational Lung Cancer Research, 2015
A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib.
Xing K et al.
Medical Oncology (northwood, London, England), 2014
EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer.
Fang S et al.
Drug Design, Development and Therapy, 2014
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Wu JY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011